{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:08:49Z","timestamp":1781953729700,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016952","name":"Cogent Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2023.120.1"],"award-info":[{"award-number":["2023.120.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaip.2025.10.034","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:18:28Z","timestamp":1762215508000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis"],"prefix":"10.1016","volume":"14","author":[{"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Luebke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.10.034_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2025.10.034_bib4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.2023022416","article-title":"How I diagnose and treat systemic mastocytosis with an associated hematologic neoplasm","volume":"145","author":"Radia","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","article-title":"Mastocytosis","volume":"11","author":"Akin","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.10.034_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ajcp\/aqae047","article-title":"How I diagnose systemic mastocytosis","volume":"162","author":"Rets","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jaip.2025.10.034_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41375-024-02504-3","article-title":"Prognostic impact of expression of CD2, CD25, and\/or CD30 in\/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis","volume":"39","author":"R\u00fcfer","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib9","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/bloodadvances.2024012756","article-title":"Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM","volume":"8","author":"L\u00fcbke","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2025.10.034_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaip.2022.10.051","article-title":"Prognostic impact of organomegaly in mastocytosis: an analysis of the European Competence Network on Mastocytosis","volume":"11","author":"L\u00fcbke","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.034_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaip.2025.10.034_bib12","first-page":"159","article-title":"Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology","volume":"3","author":"Valent","year":"2013","journal-title":"J Cancer Res"},{"key":"10.1016\/j.jaip.2025.10.034_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2025.10.034_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2025.10.034_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry","volume":"7","author":"Kennedy","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2025.10.034_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib17","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2025.10.034_bib18","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaip.2025.10.034_bib19","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2025.10.034_bib20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2025.10.034_bib21","series-title":"Presented at DGHO Annual Meeting","article-title":"Overall survival in patients with advanced systemic mastocytosis receiving avapritinib versus midostaurin or cladribine","author":"L\u00fcbke","year":"2022"},{"key":"10.1016\/j.jaip.2025.10.034_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.034_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/hematology.2023000505","article-title":"Mastocytosis demystified","volume":"2023","author":"Veitch","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaip.2025.10.034_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib25","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.10.034_bib26","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S2152-2650(24)01421-6","article-title":"MPN-274 Avapritinib in patients with advanced systemic mastocytosis (AdvSM): efficacy and safety analysis from the phase 2 PATHFINDER study with 3-year follow-up","volume":"24","author":"Reiter","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaip.2025.10.034_bib27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2025.10.034_bib28","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2025.10.034_bib29","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib30","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"issue":"Suppl.","key":"10.1016\/j.jaip.2025.10.034_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2024-193760","article-title":"Redefining prognosis in patients with KIT D816V positive advanced systemic mastocytosis on KIT inhibitors","volume":"144","author":"L\u00fcbke","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib32","series-title":"Presented at EHA Annual Congress","article-title":"The revised mutation-adjusted risk score (MARS-R) for predicting overall survival in patients with advanced systemic mastocytosis treated with midostaurin or avapritinib","author":"L\u00fcbke","year":"2025"},{"key":"10.1016\/j.jaip.2025.10.034_bib33","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaip.2025.10.034_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41375-024-02186-x","article-title":"Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries","volume":"38","author":"L\u00fcbke","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib35","article-title":"Advanced systemic mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant","volume":"71","author":"Sriskandarajah","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jaip.2025.10.034_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13023-021-02035-5","article-title":"Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF","volume":"16","author":"Taylor","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2025.10.034_bib38","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis","volume":"40","author":"L\u00fcbke","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaip.2025.10.034_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jaip.2022.12.016","article-title":"Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin","volume":"11","author":"Voelker","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.034_bib40","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.jaip.2019.05.032","article-title":"Treatment of systemic mastocytosis in an infant with midostaurin","volume":"7","author":"Liu","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.034_bib41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/bjh.70065","article-title":"Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis","volume":"207","author":"L\u00fcbke","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2025.10.034_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14712598.2021.1837109","article-title":"Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin","volume":"21","author":"Gotlib","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaip.2025.10.034_bib43","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaip.2025.10.034_bib44","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.034_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"issue":"Suppl. 1","key":"10.1016\/j.jaip.2025.10.034_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2024-193678","article-title":"Apex part 1: updated assessment of bezuclastinib (CGT9486), a selective KIT D816V tyrosine kinase inhibitor, in patients with advanced systemic mastocytosis (AdvSM)","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jaip.2025.10.034_bib47","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1182\/blood-2024-194551","volume":"144","author":"Rein","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jaip.2025.10.034_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2023-188904","article-title":"Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: analysis of the harbor trial","volume":"142","author":"Tashi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.034_bib49","first-page":"699","article-title":"Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations on behalf of the EBMT practice harmonisation and guidelines committee","volume":"38","author":"McLornan","year":"2024","journal-title":"Leukemia"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825010219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825010219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:47:46Z","timestamp":1773917266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825010219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2213219825010219"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.10.034","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}